Nurix Therapeutics To Carry 40% Of Clinical Development Costs Of Bexobrutideg, Roche To Carry 60%
Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestones for potential total payments of up to $2.3 billion.
Nurix is teaming up with a big pharma company (Roche) to develop a medicine together. Nurix gets $700 million now and could earn more money later if the medicine works out, which shows a company believes in their project.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.